Multiple options are available for the targeted treatment of chronic lymphocytic leukemia (CLL), such as venetoclax – however the degree of response to these therapies can be varied, and repeated treatment can result in the patient exhibiting multiple resistances. Peter Hillmen, MBChB, PhD, FRCPath from St. James's University Hospital, Leeds, UK describes the impact that these targeted treatments can have on patients, and talks about how a combination of these therapies may be the way forward. This interview was recorded at the 2017 British Society for Hematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
